J&J plans for capped, flex­i­ble dos­ing af­ter four pa­tient deaths in ear­ly study of ac­tini­um prostate can­cer drug

An ex­per­i­men­tal prostate can­cer drug de­vel­oped by John­son & John­son that us­es a rare ra­dioac­tive par­ti­cle called ac­tini­um-225 led to three pa­tients see­ing their tu­mors …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER